Showing 6841-6850 of 20413 results for "".
Prurigo Nodularis in Skin of Color: Recognizing Distinct Clinical Presentations
https://reachmd.com/programs/dermatology-hub-neuroimmune-network/prurigo-nodularis-in-skin-of-color-recognizing-distinct-clinical-presentations/57012/Cheri Frey, MD, discusses how prurigo nodularis may present differently in patients with skin of color, highlighting diagnostic challenges, variations in inflammation, and the importance of recognizing disease manifestations across diverse skin tones.By the Numbers
https://reachmd.com/ma-issues-index/may-jun-2026-issue/by-the-numbers/59179/As Modern Aesthetics continues to explore the forces shaping the future of aesthetic medicine, we are excited to introduce By the Numbers, a new data-driven column created in partnership with Guidepoint Qsight. Leveraging Guidepoint Qsight Sales Measurement—a comprehensive data intelligence platformAddressing Asian Hate in Healthcare
https://reachmd.com/ma-issues-index/may-jun-2026-issue/addressing-asian-hate-in-healthcare/59173/Clinicians can be proactive in minimizing the impact of racial inequities and discrimination in the practice setting.Advancing Management of Extrapulmonary NEC: The Emerging Role of DLL3
https://reachmd.com/programs/project-oncology/extrapulmonary-nec-dll3/48916/DLL3 is emerging as a promising and actionable biomarker in extrapulmonary neuroendocrine carcinoma (NEC), with growing evidence supporting its role in guiding targeted therapies. Join Dr. Charles Turck and Dr. Rohit Thummalapalli, a gastrointestinal medical oncologist at Memorial Sloan Kettering CaPsoriasis and Mental Health: Why Whole-Patient Care Matters
https://reachmd.com/programs/frontlines-psoriasis/psoriasis-mental-health/56916/Psoriasis is more than a skin disease—it's a chronic, immune-mediated condition associated with significant psychiatric and psychosocial comorbidities, including depression, anxiety, and suicidal ideation. In this conversation with Dr. Steve Jackson, Dr. Margo Gkini shares practical strategies for sAccess to Care Shouldn’t Limit Asthma Outcomes: An Expert's Perspective
https://reachmd.com/programs/clinicians-roundtable/access-to-care-asthma-outcomes/54193/Barriers like cost, insurance-driven medication switches, and complex access requirements can negatively impact asthma outcomes and reduce adherence, particularly among vulnerable populations. Join Dr. Marcus Shaker as he discusses how systemic changes to improve access and address health equity couMaking Asthma Care Simpler with SMART Therapy
https://reachmd.com/programs/clinicians-roundtable/asthma-care-simpler-smart-therapy/54192/SMART therapy simplifies asthma management by combining maintenance and reliever treatment into a single inhaler, improving adherence and addressing barriers like health literacy and access. Hear Dr. Marcus Shaker talk about how expanding over-the-counter access to SMART therapy could reduce exacerbHow Precision Medicine Is Transforming Asthma Care
https://reachmd.com/programs/clinicians-roundtable/how-precision-medicine-is-transforming-asthma-care/54194/Advances in precision medicine are transforming severe asthma care by identifying distinct patient phenotypes and using biomarkers to guide targeted treatment. Tune in to hear Dr. Sally Wenzel explore how matching the right biologic therapy to the right patient can lead to more effective—and even liUnderstanding the Many Drivers of Severe Asthma
https://reachmd.com/programs/clinicians-roundtable/understanding-the-many-drivers-of-severe-asthma/54195/A more comprehensive approach to severe asthma care considers not only molecular drivers but also the environmental and social factors that shape disease outcomes. Hear Dr. Sally Wenzel discuss how a more holistic approach could enhance personalization and improve care for patients with this conditiDPYD Testing Before Fluoropyrimidine Therapy: Benefits, Risks, and Guidance
https://reachmd.com/programs/project-oncology/dpyd-testing-fluoropyrimidine-therapy-guidance/50998/DPYD testing has emerged as a critical standard of care for patients receiving fluoropyrimidine-based chemotherapy, with growing evidence supporting its role in reducing severe toxicity. That’s why Dr. Daniel Hertz joins us to review the clinical benefits of pretreatment testing alongside key limita